Efficacy and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus day 1-only for platinum-sensitive recurrent epithelial ovarian cancer
| Autor: | Erika J Lampert, Peter G Rose, Meng Yao, Robert DeBernardo, Roberto J Vargas, Chad M Michener, Laura M Chambers |
|---|---|
| Rok vydání: | 2023 |
| Předmět: | |
| Zdroj: | International Journal of Gynecologic Cancer. :ijgc-2022 |
| ISSN: | 1525-1438 1048-891X |
| DOI: | 10.1136/ijgc-2022-004199 |
| Popis: | ObjectiveTo compare response rate, progression-free survival, overall survival, and toxicity of carboplatin and gemcitabine administered on day 1 and day 8 (day1&8) versus a modified day 1-only regimen in recurrent platinum-sensitive ovarian cancer.MethodsA retrospective single-institution cohort study was performed in women with recurrent platinum-sensitive ovarian cancer between January 2009 and December 2020 treated with carboplatin and gemcitabine on a 21-day cycle. The impact of dosing schedule on response rate, progression-free survival, overall survival, and toxicities was assessed with univariate and multivariate models.ResultsOf 200 patients, 26% (n=52) completed day 1&8, 21.5% (n=43) started day 1&8 but dropped day 8, and 52.5% (n=105) received day 1-only. There were no differences in demographics. Median starting carboplatin and gemcitabine doses were area under curve (AUC) 5 and 600 mg/m2for day 1-only versus AUC4 and 750 mg/m2among day 1&8, respectively (pConclusionsThere was no difference in response rate, progression-free survival, or overall survival for day 1&8 versus day 1-only, regardless of whether day 8 was dropped. Day 1&8 was associated with greater hematologic toxicity. A modified day 1-only regimen may represent an alternative to day 1&8 and warrants prospective study. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|